Cencora, Inc. (NYSE:COR) Shares Acquired by Kathmere Capital Management LLC

Kathmere Capital Management LLC boosted its holdings in Cencora, Inc. (NYSE:COR) by 14.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,091 shares of the company’s stock after acquiring an additional 266 shares during the period. Kathmere Capital Management LLC’s holdings in Cencora were worth $470,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP boosted its stake in Cencora by 10.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,262,882 shares of the company’s stock valued at $284,544,000 after purchasing an additional 119,927 shares during the period. Virtu Financial LLC acquired a new position in shares of Cencora in the 2nd quarter worth approximately $1,086,000. Denali Advisors LLC grew its position in Cencora by 6.3% in the second quarter. Denali Advisors LLC now owns 1,700 shares of the company’s stock worth $383,000 after buying an additional 100 shares during the last quarter. Axxcess Wealth Management LLC grew its holdings in shares of Cencora by 5.8% in the 2nd quarter. Axxcess Wealth Management LLC now owns 9,488 shares of the company’s stock worth $2,138,000 after acquiring an additional 517 shares during the last quarter. Finally, SYSTM Wealth Solutions LLC acquired a new stake in Cencora during the 2nd quarter worth about $36,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock valued at $22,862,734 in the last 90 days. 15.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on COR shares. UBS Group boosted their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Leerink Partners reduced their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Wells Fargo & Company decreased their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. Finally, Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.60.

Cencora Price Performance

Shares of COR stock opened at $237.74 on Thursday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $253.27. The company has a market capitalization of $45.95 billion, a P/E ratio of 31.66, a P/E/G ratio of 1.54 and a beta of 0.49. The stock has a 50 day moving average of $237.79 and a two-hundred day moving average of $233.67. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.93%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is currently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.